Scotland’s medicines regulator has rejected sotatercept for PAH, citing insufficient cost-effectiveness evidence despite improved exercise capacity.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/smc-rejects-sotatercept-pulmonary-hypertension-2026a100042g?src=rss
Author :
Publish date : 2026-02-09 17:08:00
Copyright for syndicated content belongs to the linked Source.
